Evidence map›Paper›PMID 42098112›Full record

ArticleNature communications2026

Triose phosphate isomerase 1 remodels mitochondrial cristae ultrastructure to rewire microglial immunometabolism against ischemic stroke.

Xiao-Wen Zhang, Xiao-Ming Ye, Ran Wang, Yong-Dong Guo, Ling Li, Yang Chen, Ting-Ting Liu, Xiao-Qing Zhou, Yu-Qi Wang, Zhong-Yao Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiao-Wen Zhang *State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Xiao-Ming Ye *State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0009-0007-0151-1469
Ran Wang *Shandong Academy of Pharmaceutical Sciences, New Sustained and Controlled Release Formulations and Drug Targeted Delivery System Shandong Engineering Research Center, Jinan, China.
Yong-Dong Guo *Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China.
Ling LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yang ChenState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Ting-Ting LiuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Xiao-Qing ZhouState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yu-Qi WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Zhong-Yao LiInstitute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Zhi-Yuan LuInstitute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.ORCID http://orcid.org/0000-0001-8969-6195
Zhi-Yong DuBeijing Institute of Heart, Lung and Blood Vessel Disease, National Clinical Research Center for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Wei ZhouState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0001-5486-4849
Bo HanSchool of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Shihezi University, Shihezi, China.ORCID http://orcid.org/0000-0002-6509-0313
Peng-Fei TuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China. pengfeitu@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-3848-8174
Qi-Xin ChenShandong Academy of Pharmaceutical Sciences, New Sustained and Controlled Release Formulations and Drug Targeted Delivery System Shandong Engineering Research Center, Jinan, China. chenqixin@sdfmu.edu.cn.ORCID http://orcid.org/0000-0002-2998-5582
Chun-Hong ZhengDepartment of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China. chunhong_zheng@bjmu.edu.cn.ORCID http://orcid.org/0009-0004-9991-9080
Ke-Wu ZengState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China. ZKW@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-1082-6327

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82174008National Natural Science Foundation of China (National Science Foundation of China) 82325050
6 · The paper itself

Abstract

Mitochondrial cristae ultrastructure enables ATP synthase organization for adaptive energy production. This process is critical for regulating microglia mediated neuroinflammation in ischemic stroke pathology. However, therapeutic strategies targeting cristae remodeling remain unexplored. We identified a chemical probe, icariin II (ICS), which restores mitochondrial cristae by targeting triose phosphate isomerase 1 (TPI1). ICS-induced TPI1 conformational switching recruits ATP5MF to drive F

Indexed as

Ischemic StrokeMicrogliaMitochondriaTriose-Phosphate IsomeraseAnimalsCardiolipinsDisease Models, AnimalDNA, MitochondrialHumansInfarction, Middle Cerebral ArteryMaleMitochondrial MembranesMitochondrial Proton-Translocating ATPasesOxidative PhosphorylationRatsRats, Sprague-DawleyCardiolipinsDNA, MitochondrialMitochondrial Proton-Translocating ATPasesTriose-Phosphate Isomerase

Identifiers

PMID42098112
PMCPMC13365430

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.